On August 19, INNOVENT BIO rose 3.47% in regular trading, trading at HK$99.7/share, with turnover of HK$602 million.

On the news front, BlackRock increased its holdings by 139,500 shares on August 12 at HK$95.375 per share, bringing its stake to 5.01% with approximately 87.32 million shares held, totaling around HK$13.3 million in value. The institutional endorsement comes ahead of the company's board meeting scheduled for August 25 to review interim results.

The company previously disclosed H1 product revenue exceeding RMB 8.2 billion, representing year-over-year growth of over 55%, with Q2 product revenue surpassing RMB 4.3 billion, up approximately 60% YoY — significantly beating market expectations. Goldman Sachs raised its target price to HK$111.68, while BOCOM International set a target of HK$118, both maintaining buy ratings. Additionally, the company recently partnered with Meituan to explore instant retail channels, further expanding its commercialization reach.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)